TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway
Conclusion We demonstrate that pharmacologic inhibition of the inositol pyrophosphate pathway has strong therapeutic potential in obesity, T2D, and other metabolic diseases.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
More News: Asthma | Cardiology | Coronary Heart Disease | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Disease | Insulin | Neurology | Nutrition | Obesity | Osteoarthritis | Stroke | Study | Weight Loss